Business Context and Reporting Period
This Form 8-K Current Report was filed by Silence Therapeutics plc on December 18, 2025. The filing reports a corporate governance event: the appointment of a new Executive Director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Rhonda Hellums, the Company's Executive Vice President and Chief Financial Officer, to the Board of Directors, effective immediately on December 18, 2025.
Guidance, Outlook, and Management Commentary
- Term of Service: Ms. Hellums will serve an initial term expiring at the end of the Company's 2026 Annual General Meeting of Shareholders.
- Committee Assignments: As an executive director, she will not be appointed to serve on any committee of the Board.
- Compensation: Ms. Hellums will not receive additional compensation for her service as a member of the Board.
- Relationships: There are no family relationships between Ms. Hellums and other directors or officers, and no undisclosed arrangements regarding her selection.
Important Facts for Investor Verification
- Confirm the effective date of the Board appointment (December 18, 2025).
- Verify that no additional compensation is being paid for the Board role beyond existing executive compensation.
- Review the definitive proxy statement filed on May 16, 2025, for Ms. Hellums' full biography.
- Note that this filing does not impact the Company's financial statements or operational guidance.